BTIG initiated coverage of Cartesian Therapeutics (RNAC) with a Buy rating and $42 price target Cartesian is pioneering the field of mRNA-based CART cell therapies for autoimmune disorders, the analyst tells investors in a research note. The firm says the company’s lead efforts are in myasthenia gravis, which has provided “important proof of concept for Descartes-08 with differentiated efficacy that looks progressive through long-term follow-up.” BTIG sees an attractive entry point for investors ahead of MG Phase 3 initiation in the first half of 2025.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics announces employment inducement grants
- Cartesian Therapeutics files to sell 11.39M shares of common stock for holders
- Cartesian Therapeutics files to sell 6.25M shares of common stock for holders
- Cartesian Therapeutics files $400M mixed securities shelf
- Cartesian Therapeutics price target raised to $45 from $41 at H.C. Wainwright